Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00817986 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms
A Phase 2 study, sponsored by XenoPort.
- Completed
- Registry status
- Phase 2
- Development phase
- 161
- Enrollment target
NCT00817986 is a Phase 2 study that has completed, run by XenoPort. The registered enrollment target is 161 participants.
The verdict
NCT00817986, a Phase 2 study, has completed, sponsored by XenoPort.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 161 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate safety and tolerability of arbaclofen placarbil sustained release tablets taken every 12 hours compared to placebo in subjects with acute back spasms in the lumbar region.
Interventions
- DRUG Placebo
- DRUG Arbaclofen placarbil, 20 mg
- DRUG Arbaclofen placarbil, 30 mg
- DRUG Arbaclofen placarbil, 40 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00817986
The ClinicalTrials.gov registry entry for NCT00817986 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is XenoPort, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00817986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00817986 about?
NCT00817986 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms". The purpose of the study is to evaluate safety and tolerability of arbaclofen placarbil sustained release tablets taken every 12 hours compared to placebo in subjects with acute back spasms in the lumbar region.
What is the current status of trial NCT00817986?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 161 participants. The study started on 2008-12. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00817986?
The interventions under investigation include: Placebo (DRUG), Arbaclofen placarbil, 20 mg (DRUG), Arbaclofen placarbil, 30 mg (DRUG), Arbaclofen placarbil, 40 mg (DRUG).
Who is sponsoring clinical trial NCT00817986?
This trial is sponsored by XenoPort, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.